CD200 is a membrane glycoprotein that suppresses immune activity via its receptor, CD200R. CD200-CD200R interactions have recently been considered to contribute to the Bimmune privileged[ status of the central nervous system (CNS). The mechanisms by which these interactions take place are not well understood in part because there is limited detailed information on the distribution of CD200 and CD200R in the CNS. Here, we used immunohistochemistry to characterize the distinct anatomical and cellular distribution of these molecules in multiple sclerosis (MS) lesions and controls. CD200 was robustly expressed in gray matter areas including the cerebral cortex, hippocampus, striatum, cerebellum, and spinal cord, where neurons appeared immunopositive. CD200 expression was also detected in oligodendrocytes, but not in astrocytes or microglia. In CNS samples from MS patients, CD200 expression was additionally observed on reactive astrocytes in chronic active plaque centers, despite our previous finding of an overall decrease of CD200 expression in MS lesions. In contrast to CD200, the immunolocalization pattern of CD200R was very distinct, showing high expression on perivascular macrophages in both gray and white matter. Using flow cytometry, we also found that human primary microglia express low levels of CD200R. These data suggest that CD200-mediated immune suppression may occur not only via neuron-microglia interactions, but also via glia-glia interactions, especially in inflammatory conditions in which an immune-suppressive environment needs to be restored; this may occur as a result of increased CD200 expression on reactive astrocytes.
INTRODUCTION
Cells in the central nervous system (CNS) have a low capacity for regeneration and therefore require protection from potentially injurious peripheral immune responses. Several strategies create an Bimmune privileged[ environment, the physiology of which is only partly understood. One of the beststudied components of CNS immune privilege is the bloodbrain barrier, which restricts the entrance of leukocytes into the CNS. In addition, a deficient communication between the CNS and the peripheral immune system involves the afferent arm of the immune system and is established by the lack of competent antigen-presenting cells and a conventional lymphatic system (1) . Moreover, microglia, the resident antigenpresenting macrophages that are present throughout the CNS and may contribute to deleterious neuroimmune processes, also need to be continually constrained. Mechanisms that may directly inhibit peripheral and central immune responses are, therefore, highly important for CNS protection but are less well studied. One potential mechanism involves CD200, which is highly expressed on neurons and can downregulate immune activity through binding of its receptor CD200R (2Y4). The likelihood that CD200-CD200R interactions in the CNS contribute to immune privilege is indicated by the observation that CD200 expression is very high in other immune-suppressed organs such as the placenta (5) . CD200 and its receptor are homologous membrane glycoproteins that belong to the immunoglobulin superfamily. CD200 is expressed on numerous cell types in a wide variety of tissues (5) , whereas in humans, CD200R is mainly expressed on myeloid cells (e.g. monocytes and macrophages) and on a subset of T and B cells (6, 7) . CD200R has also been demonstrated on microglia in rats (4, 8) . Unlike its ligand, CD200R has signaling motifs in its intracellular domain that deliver an inhibitory signal to the cell upon triggering (7, 9) . CD200 is highly expressed in the CNS of rodents; CD200-deficient mice have spontaneously activated microglia and show an enhanced susceptibility to several inflammatory disease models including experimental autoimmune uveoretinitis and experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS) (2, 10) . Conversely, mice with inherently increased levels of CD200 because of a mutation in the Wld Copyright @ 2009 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
EAE, have milder clinical disease, and show increased neuroprotection (11) .
Thus, animal models demonstrate that loss of immune suppression via CD200 in the CNS has marked effects on neuroinflammation and neurodegeneration. Activated microglia are associated with neurodegeneration in human aging, as well as in diseases such as stroke, MS, Alzheimer disease, and Parkinson disease. In addition, in MS, leukocyte infiltration contributes to the pathogenesis of multiple demyelinated lesions. Recently, we found that the expression of CD200, but not CD200R, was diminished in and around MS lesions; this loss may permit macrophage/microglia activation and inflammation in the CNS of MS patients (12) . CD200 has been shown to be expressed on neurons in the rat CNS and in the human retina (3, 8) , but there is little detailed information on CD200-CD200R expression in the human CNS. By identifying the cells that express CD200 and its receptor, we gain insight into the mechanisms by which these molecules may suppress deleterious inflammatory responses in the CNS. This information may help delineate targets for therapeutic approaches that might restore immune suppression when needed, for example, in MS. Here, we report broad anatomical distribution and cellular localization of CD200 and CD200R in the human CNS, and demonstrate that CD200R is expressed at low levels on human microglia and that CD200 expression is not only restricted to neurons but can also be expressed by glial cells, in particular MS lesions.
MATERIALS AND METHODS

Tissue and Donors
Snap-frozen tissue specimens of parietal cortex, hippocampus, hypothalamus, cerebellum, and spinal cord of 3 control subjects and white matter lesions of 8 MS patients obtained at autopsy were provided by the Netherlands Brain Bank, Netherlands Institute for Neuroscience, Amsterdam. Permission was obtained for brain autopsy and the use of the tissue and clinical information for research purposes. All patients were clinically diagnosed as having MS by a neurologist (Prof C. H. Polman, VU Medical Center Amsterdam), and the diagnosis was confirmed postmortem by a neuropathologist. Donor characteristics are shown in the Table.
Immunohistochemistry
Cryostat sections, 8-Km-thick, were fixed in acetone for 10 minutes. The sections were then incubated with monoclonal antibodies to the following: CD200 (Clone OX104 for human and OX90 for mouse tissue, hybridomas were kindly provided by Dr A. N. Barclay, University of Oxford, UK, as has been previously described [5] ); CD200R (Clone OX108 [13] , Serotec, Oxford, UK); or mannose receptor (Clone 15-2, Serotec). The antibodies were diluted in PBS containing 1% bovine serum albumin (BSA), overnight at 4-C. After washing in PBS, the sections were incubated with secondary antibody dilutions of biotinylated horse antimouse immunoglobulin G ([IgG] Vector Laboratories, Burlingame, CA) containing 10% horse serum for 45 minutes, followed by a 45-minute incubation in horseradish peroxidaseY conjugated avidin-biotin-complex ([ABC] Vectastain ABC Elite Kit, Vector Laboratories). To amplify the staining, CD200R-treated sections were incubated with biotinylated tyramine (14) , with the addition of 0.01% H 2 O 2 for 10 minutes, after which the sections were again incubated in ABC for 45 minutes. Staining in all sections was visualized with 3,3 ¶-diaminobenzidine (Sigma, St Louis, MO) applied for 10 minutes. Sections were counterstained with hematoxylin for 30 seconds, dehydrated, and mounted in Entellan (Merck, Darmstadt, Germany). For fluorescent CD200 double staining, the sections were first incubated with a polyclonal antibody to glial fibrillary acidic protein ([GFAP] DakoCytomation, Glostrup, Denmark) and monoclonal antibodies to CNPase (Clone 11-5B, Sigma), neurofilament (clone SMI-311R, Covance, Emeryville, CA), or Factor VIII (kindly provided by Dr L. Bö, VU Medical Center, Amsterdam, The Netherlands) for 1 hour at room temperature, followed by incubation with goatYanti-rabbit or goatYanti-mouse Alexa 594Ylabeled antibody (InvitrogenYMolecular Probes, Eugene, OR) in the presence of 10% normal goat serum for 1 hour at room temperature. The sections were then incubated with biotinylated . CD200 immunostaining in gray matter is diffuse in the neuropil (A, B, E, F). CD200 staining in white matter is more distinct and may be present on nonneuronal elements.
Multiple sclerosis lesion inflammatory activity was characterized as previously described in cryostat sections (8 Km) stained for myelin proteolipid protein (Serotec) and human leukocyte antigenYDP, DQ, DR (Clone CR3/43, Dako) (12, 15Y17). We used 4 chronic active lesions, as determined by the presence of human leukocyte antigenYpositive foamy macrophages in the rim surrounding the gliotic lesion center and 4 inactive lesions, as determined by the absence of foamy macrophages.
Human Microglia Isolation
Corpus callosum white matter, provided by the Netherlands Brain Bank, was obtained at autopsy and stored in Hibernate A medium (Brain Bits LLC, Springfield, IL) at 4-C. Within 5 to 18 hours after autopsy, microglia were isolated using a Percoll gradient (GE Healthcare, Diegem, Belgium), as previously described (18), with some adaptations. In brief, tissue (per gram) was mechanically dissociated using a metal sieve in a total volume of 50 mL GKN/0.
HH).
After centrifugation (400 Â g, 7 minutes), the pellet was reconstituted in 5 mL of dissociation buffer (4 g/L MgCl 2 , 2.55 g/L CaCl 2 , 3.73 g/L KCl, 8.95 g/L NaCl, pH 6-7) and enzymatically digested in 200 Kg/mL DNase I (Roche Diagnostics, Mannheim, Germany) and 150 U collagenase Type I (Worthington, Lakewood, NJ) for 1 hour at 37-C. During this incubation, the tissue was mechanically disrupted by passing the mixture through a pipette tip with decreasing bore size every 5 to 10 minutes. After washing in GKN/0.2% 
Flow Cytometry
The freshly isolated CNS cells were incubated with fluorescein isothiocyanateYlabeled antibody against human CD45 (Clone HI30), phycoerythrin-labeled CD11b (Clone ICRF44, Dako), and Alexa 647Ylabeled CD200R (Clone OX108, Serotec) or with the appropriate isotype controls in the presence of 10% human pool serum for 1 hour at 4-C. Antibody dilutions and washing steps were performed in FACS buffer (i.e. PBS, 0.2% BSA, 10 mmol/L sodium azide). After washing, the cells were analyzed using a FACSCalibur flow cytometer (BD PharMingen, San Jose, CA), and the data were analyzed using FlowJo software version 8.7.1 (Treestar, Inc, Ashland, OR). Cells were sorted on a FACS Aria cell sorter (BD PharMingen).
RESULTS
Anatomical and Cellular CD200 Expression in the Normal Human CNS CD200 was broadly expressed throughout the control human CNS samples. In Figure 1 , examples are shown of immunostaining in parietal cortex, hippocampus, striatum, cerebellum, and spinal cord. The most intense CD200 immunostaining was in cortical gray matter in which neurons appeared CD200 positive (Figs. 1A, B, insets) . Although CD200 immunoreactivity seemed to be present on the neuronal cell membrane, this was difficult to determine because staining was diffusely present between neuronal cell bodies; in hippocampal neurons, for example, staining also seemed to be present in the cytoplasm (Fig. 1B) . CD200 staining in the striatum was less abundant in white matter bundles and was more concentrated in the gray matter (Figs. 1C, D) ; in the cerebellum, it was predominantly expressed in the granular and molecular layers (Figs. 1E, F) . The membranes of Purkinje neurons appeared to be immunopositive, but the cytoplasm was unstained (Fig. 1F, inset) . In agreement with our earlier report, CD200 was also present on axons (Figs. 1G, H) (12) . Transversal sections of the spinal cord showed that the myelin surrounding the axons was unstained, but CD200 was expressed on elements surrounding the myelin sheaths (Fig. 1G, inset) . This staining pattern suggests that CD200 expression may not be limited to neurons and their axons.
By immunofluorescent double staining, we confirmed that axons expressed CD200, as indicated by colocalization with neurofilament in a longitudinal section of the spinal cord ( Fig. 2A) . The fluorescent images confirmed that CD200 expression was broad and not limited to axons. Double labeling of a transverse section of spinal cord with CNPase showed that the elements surrounding the myelin sheaths seen in Figure 1G were likely oligodendrocytes that expressed CD200 (Fig. 2B) . In addition, CNPase and CD200 labeling in white matter clearly showed colocalization on oligodendrocyte cell bodies (Fig. 2C) . No colocalization of CD200 with GFAP was found, however, indicating that in the nondiseased CNS, astrocytes do not express CD200 (Fig. 2D) . Microglia also did not express CD200 because no colocalization with CD11b was found (data not shown). Despite the fact that CD200 expression has been described on vascular endothelial cells in the rat cerebellum (3) and in the human liver (5), we could not find CD200 colocalization with the endothelial marker Factor VIII, indicating that human brain vascular endothelium did not express CD200 (data not shown).
CD200 Expression in MS Lesions
Because we previously demonstrated that CD200 expression in MS lesions was decreased, we analyzed cellular CD200 expression in MS lesions by immunohistochemistry. In MS lesion borders and in the tissue adjacent to the lesions, oligodendrocytes were CD200 positive (Fig. 3A) ; staining of both CNPase and CD200 was diminished in lesion centers FIGURE 4 . CD200 expression in cryosections of the mouse CNS. (A) CD200 immunoreactivity is present in both gray and white matter areas, but staining intensity is low in white matter areas such as the corpus callosum and tracts in the striatum compared with gray matter in which CD200 staining is diffuse. (B) CD200 staining is predominant in the granular and molecular layers of the cerebellum and sparse in Purkinje cells and white matter (right side of field). Scale bars = (A) 500 Km; (B) 65 Km. (data not shown, see also Koning et al [12] ). Unexpectedly, a subpopulation of GFAP-positive astrocytes in chronic active MS lesions also expressed CD200 (Fig. 3B) . These lesionassociated astrocytes were all hypertrophic as determined by their characteristic morphology; astrocytes situated further from the lesions did not express CD200.
CD200 Expression in the Normal Mouse Brain
Although CD200 expression has been described in the rodent brain, this has been poorly documented. We found CD200 expression pattern in the mouse brain to be similar to those in the human CNS (Fig. 4) . It was abundantly present throughout the brain, and staining was highly intense in the gray matter. Staining was absent in CD200 -/-mice (data not shown) (2, 3, 19) .
Anatomical and Cellular CD200R Expression in the CNS
Although CD200R immunoreactivity was present throughout the parietal cortex, hippocampus, striatum, cerebellum, and spinal cord, its expression pattern was completely different from its ligand. CD200R in both gray and white matter was limited to cells associated with blood vessels (Figs. 5A, B) ; staining of adjacent sections with an antibody to the mannose receptor demonstrated that these cells were perivascular macrophages (Figs. 5C, D) (20) .
The immunohistochemical techniques used did not show CD200R immunoreactivity on human microglia. By contrast, studies in rodents have shown that CD200R is expressed on microglia, but these were reported at low levels using flow cytometry and were also not supported by immunohistochemistry (4, 19) . Therefore, we analyzed CD 200R expression on primary microglia freshly isolated from human autopsy material using the highly sensitive technique of flow cytometry. We found that CD45 dim CD11b + human microglia reproducibly expressed low amounts of CD200R (Fig. 5E ). In addition, gene expression analysis on these isolated FACS-sorted cells confirmed the presence of CD200R transcript, but expression of CD200R on choroid plexusYderived macrophages and peripheral blood monocytes was markedly higher (data not shown) (7). In both chronic active and inactive MS lesions, CD200R immunostaining was clearly visible on blood vesselYassociated cells in all areas of the lesions and in the normal-appearing white matter surrounding them. In chronic active MS lesions, some perivascular cuffs contained CD 200R-positive cells, whereas others did not (Figs. 6A, B) . CD200R expression was also occasionally present on perivascular but not parenchymal foamy macrophages (Fig. 6C) .
DISCUSSION
In this study, we show that human CNS neurons express CD200, likely on the cell membrane and in the cytoplasm in some. This confirms previous observations on the rat CNS and the human retina (3, 8) . The cytoplasmic staining visible in some neurons may reflect transport of CD200 from the Golgi to the cell membrane. It is not clear why this was not seen in the cytoplasm of all neurons (e.g. that of Purkinje cells was negative), although this might indicate differential turnover rates of CD200 on these neurons. We are the first to report that human microglia express CD200R. Taken together, these data indicate that neurons may suppress microglia via CD200-CD200R interaction to protect themselves from deleterious inflammatory reactions, as previously postulated for rodents. CD200 was present on axons in white matter, but it was not clear how axonal CD200 might bind its receptor because the axon is covered with myelin, except at the nodes of Ranvier. For CD200-CD200R interactions to mediate immune suppression in white matter, it would be necessary for CD200 to be expressed by cells surrounding axons. Indeed, we found that CNPase-positive oligodendrocytes, but not GFAP-positive astrocytes, expressed CD200. Hence, these results strongly suggest that not only neuron-glia but also glia-glia interactions are involved in the control of microglia activation in white matter.
The immunostaining pattern of CD200 in gray matter is peculiar and difficult to interpret. The staining was diffuse and present on and between neuronal cell bodies. Although most of the immune reactivity is ascribed to neurons, it is possible that oligodendrocytes also account for the interneuronal staining. It is unlikely that the diffuse staining is caused by secretion of CD200 because it is a membranebound glycoprotein encompassing a transmembrane domain, and lacking any known proteinase motifs that would be necessary for its release (21) . The diffuse staining pattern cannot be attributed to nonspecificity of the antibody because this was ruled out by specificity tests for this antibody (5) . Furthermore, immunoreactivity was absent in control stainings that included isotype-matched antibodies. Moreover, CD200 expression in the CNS of mice showed a similar pattern as that in the human CNS, whereas staining was completely absent in CD200 j/j mice, thereby confirming CD200 staining specificity. Finally, diffuse expression patterns are not uncommon in the CNS; for example, the synaptic modulatory phosphoprotein GAP43 has been extensively described as a neuron-specific protein but shows an expression pattern in gray matter areas resembling that of CD200 (22, 23) .
In contrast to the astrocytes in control CNS samples, CD200 was expressed in reactive astrocytes associated with MS lesions. This was a surprising finding because we recently showed that the overall expression levels of CD200 are decreased in the center and rim of MS lesions (12) . This decreased expression is presumably caused by axonal and oligodendrocyte damage and may enhance macrophage and microglia activation. Because activated macrophages and microglia are thought to drive lesion formation in MS (24) , loss of CD200 would thus permit enhanced inflammation and disease progression, as in the animal models. The implications for neuronal integrity are clearly reflected in enhanced neuronal damage in these in vivo models and also in macrophageneuronal cocultures (2, 10, 25) , whereas animals with increased CD200 levels display enhanced neuroprotection (11) . Our data on CD200-positive reactive astrocytes now suggest that immune activation within the CNS may lead to a protective molecular response by astrocytes that otherwise do not express CD200. Moreover, the data corroborate the idea that astrocytes are protective and neurotrophic (26) . CD200 immunoreactivity in MS lesions was, however, still decreased overall compared with control tissues, indicating that this mechanism for restoring CNS immune suppression in MS fails.
Expression of CD200R on microglia could not be detected using immunohistochemistry, but we demonstrate that human primary microglia expressed low levels of CD200R by flow cytometry, a finding that has also been noted in rodents (4, 19) . In contrast to microglia, CD200R was intensely stained on macrophages located in the perivascular space in close proximity to CD200-negative vascular endothelium. Hence, it is likely that in an environment in which CD200 is abundantly present, CD200R expression is downregulated.
In conclusion, many molecules have been implicated in the activation of macrophages and microglia, such as those derived from cellular debris to apoptotic cells. Molecules such as CD200 suppress the activation of myeloid cells to limit tissue damage, thereby protecting the vulnerable neurons from deleterious effects of inflammation (27, 28) . Importantly, oligodendrocytes and astrocytes can also mediate neuroprotection by direct cell-cell contact through CD200-CD200R, in addition to the release of, for example, neurotrophic factors. Dysregulation of the finely tuned resident innate immunity in the CNS may cause macrophage/microglia activation as abundantly occurs in MS and also in other neurodegenerative disorders, such as in stroke, Alzheimer disease, and Parkinson disease (29, 30) . At present, it is not known how the expression of CD200 or CD200R is regulated. This will be the next step in providing tools for therapeutic use of immune-suppressive mechanisms in the CNS in inflammatory and neurodegenerative diseases.
